We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Syneos Health (SYNH) to Launch Serplulimab With New Pact
Read MoreHide Full Article
Syneos Health, Inc. recently entered into a strategic partnership with Fosun Pharma USA — the U.S.-based subsidiary of Shanghai Fosun Pharmaceutical. The partnership will leverage Syneos One expertise, accessing its clinical and commercial solutions.
As part of the collaboration, Syneos Health will offer Full-Service Commercial support through its Syneos One team for the launch of Serplulimab — a novel anti-PD-1 antibody for extensive stage small cell lung cancer (ES-SCLC), in the United States.
More on the News
Over time, the partnership between the two companies is likely to expand further, continuing to leverage Syneos One product development team of experts and full commercial infrastructure to aid Fosun Pharma USA’s growth.
Serplulimab is the first advanced monoclonal antibody designed by Shanghai Henlius Biotech. Fosun Pharma USA has the exclusive right to commercialize Serplulimab in the United States upon regulatory approval.
It is worth mentioning that Syneos One solutions can reduce program risk and optimize product development timelines while maximizing return on investment. These solutions offer small to mid-sized customers an economical alternative to divesting, out-licensing or co-promoting assets and offer large biopharmaceutical customers further opportunities to reduce their fixed-cost infrastructure. The solutions can be an alternative approach to developing and promoting non-core and established assets.
Strategic Implications
Syneos Health will provide medical affairs, market access, marketing, sales and operations capabilities and staffing to help Fosun bring Serplulimab to market and address important unmet patient needs. The partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today’s changing environment.
Image Source: Zacks Investment Research
Per Syneos Health’s management, this partnership demonstrates the company’s ability to offer customized solutions that encompass the entire product development continuum. Syneos Health’s ability to strategize and execute across multiple service lines, including medical affairs and commercial, makes the company the leading partner for Fosun Pharma USA. The company is strategically supporting to optimize Fosun Pharma’s asset portfolio as they expand their advanced Medicine business in the United States.
Industry Prospects
Per a report by Data Bridge Market Research, the global small cell lung cancer therapeutics market was valued at $10 billion in 2021, and it is expected to grow $21.44 billion by 2029, registering a CAGR of 10%. The rise in cases of SCLC across the world and promising pipeline drugs are the factors driving the market.
Recent Developments
In December 2022, Syneos Health extended its strategic partnership with Medable as part of the company’s commitment to bring clinical trials closer to the patient. Syneos Health and Medable will continue to reduce site and patient burden, improve enrollment and retention and increase patient access and diversity through innovative decentralized clinical trial (DCT) solutions.
In October 2022, Syneos Health expanded its partnership with Datavant — the leader in helping organizations securely connect health data. The collaboration streamlines clinical trial tokenization, further enhancing medical affairs, market access and commercial analytics for clients.
Price Performance
Shares of the company have lost 62.6% in a year compared with the industry’s fall of 43.6%.
Zacks Rank and Key Picks
Currently, Syneos Health carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has lost 10.6% compared with the industry’s 30.3% decline in the past year.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.3%. BSX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 1.9%.
Boston Scientific has gained 6.8% against the industry’s 42.6% decline in the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 13.7% against the industry’s 8.7% decline in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Syneos Health (SYNH) to Launch Serplulimab With New Pact
Syneos Health, Inc. recently entered into a strategic partnership with Fosun Pharma USA — the U.S.-based subsidiary of Shanghai Fosun Pharmaceutical. The partnership will leverage Syneos One expertise, accessing its clinical and commercial solutions.
As part of the collaboration, Syneos Health will offer Full-Service Commercial support through its Syneos One team for the launch of Serplulimab — a novel anti-PD-1 antibody for extensive stage small cell lung cancer (ES-SCLC), in the United States.
More on the News
Over time, the partnership between the two companies is likely to expand further, continuing to leverage Syneos One product development team of experts and full commercial infrastructure to aid Fosun Pharma USA’s growth.
Serplulimab is the first advanced monoclonal antibody designed by Shanghai Henlius Biotech. Fosun Pharma USA has the exclusive right to commercialize Serplulimab in the United States upon regulatory approval.
It is worth mentioning that Syneos One solutions can reduce program risk and optimize product development timelines while maximizing return on investment. These solutions offer small to mid-sized customers an economical alternative to divesting, out-licensing or co-promoting assets and offer large biopharmaceutical customers further opportunities to reduce their fixed-cost infrastructure. The solutions can be an alternative approach to developing and promoting non-core and established assets.
Strategic Implications
Syneos Health will provide medical affairs, market access, marketing, sales and operations capabilities and staffing to help Fosun bring Serplulimab to market and address important unmet patient needs. The partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today’s changing environment.
Per Syneos Health’s management, this partnership demonstrates the company’s ability to offer customized solutions that encompass the entire product development continuum. Syneos Health’s ability to strategize and execute across multiple service lines, including medical affairs and commercial, makes the company the leading partner for Fosun Pharma USA. The company is strategically supporting to optimize Fosun Pharma’s asset portfolio as they expand their advanced Medicine business in the United States.
Industry Prospects
Per a report by Data Bridge Market Research, the global small cell lung cancer therapeutics market was valued at $10 billion in 2021, and it is expected to grow $21.44 billion by 2029, registering a CAGR of 10%. The rise in cases of SCLC across the world and promising pipeline drugs are the factors driving the market.
Recent Developments
In December 2022, Syneos Health extended its strategic partnership with Medable as part of the company’s commitment to bring clinical trials closer to the patient. Syneos Health and Medable will continue to reduce site and patient burden, improve enrollment and retention and increase patient access and diversity through innovative decentralized clinical trial (DCT) solutions.
In October 2022, Syneos Health expanded its partnership with Datavant — the leader in helping organizations securely connect health data. The collaboration streamlines clinical trial tokenization, further enhancing medical affairs, market access and commercial analytics for clients.
Price Performance
Shares of the company have lost 62.6% in a year compared with the industry’s fall of 43.6%.
Zacks Rank and Key Picks
Currently, Syneos Health carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has lost 10.6% compared with the industry’s 30.3% decline in the past year.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.3%. BSX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 1.9%.
Boston Scientific has gained 6.8% against the industry’s 42.6% decline in the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 13.7% against the industry’s 8.7% decline in the past year.